Ung variety two (MODY 2). Am J Physiol Endocrinol Metab 2010, 298:E512 523.15. Zhang YL, Tan XH, Xiao MF, Li H, Mao YQ, Tan HR: Establishment of liver precise glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs. Acta Pharmacol Sin 2004, 25:1659?665. 16. Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Rong Lu H, Himmelreich U, D’hooge J, Swinnen M, Lijnen HR: Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice? Eur J Pharmacol 2013, 700:23?1. 17. Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191?201. 18. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Threat of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare sufferers treated with rosiglitazone or pioglitazone.159611-02-6 Data Sheet JAMA 2010, 304:411?18. 19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412?19. 20. Bugger H, Riehle C, Jaishy B, Wende AR, Tuinei J, Chen D, Soto J, Pires KM, Boudina S, Theobald HA, Luptak I, Wayment B, Wang X, Litwin SE, Weimer BC, Abel ED: Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Molec Cell Cardiology 2012, 52:1019?026. 21. England J, Loughna S: Heavy and light roles: myosin within the morphogenesis from the heart. Cell Mol Life Sci 2013, 70:1221?239. 22. Velho G, Froguel P: Genetic, metabolic and clinical traits of maturity onset diabetes in the young. Eur J Endocrinol 1998, 138:233?39. 23. Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P: Diabetes complications in NIDDM kindreds linked towards the MODY3 locus on chromosome 12q. Diabetes Care 1996, 19:915?19. 24. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K: Clinical significance from the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001, 48:81?six. 25. Shigematsu Y, Hamada M, Nagai T, Nishimura K, Inoue K, Suzuki J, Ogimoto A, Higaki J: Risk for atrial fibrillation in sufferers with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011, 58:18?5. 26. Vecoli C, Andreassi MG, Liga R, Colombo MG, Coceani M, Carpeggiani C, L’Abbate A, Neglia D: T(-786)C polymorphism in the endothelial nitric oxide synthase gene is associated with insulin resistance in individuals with ischemic or non ischemic cardiomyopathy.Methyl dec-9-enoate structure BMC Med Gene 2012, 13:92?8.PMID:34235739 27. Weterman MA, Barth PG, van Spaendonck-Zwarts KY, Aronica E, Poll-The BT, Brouwer OF, van Tintelen JP, Qahar Z, Bradley EJ, de Wissel M, Salviati L, Angelini C, van den Heuvel L, Thomasse YE, Backx AP, N nberg G, N nberg P, Baas F: Recessive MYL2 mutations cause infantile kind I muscle fibre disease and cardiomyopathy. Brain 2013, 136:282?93. 28. Koka S, Xi L, Kukreja RC: Chronic remedy with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic modifications connected with cytoskeletal rearrangement and redox regulation in Type two diabetic hearts. Standard Res Cardiol 2012, 107:249?53. 29. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB: The effect of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Robust Heart Study. J Am Coll Cardiol 2001, 37:1943?949. 30. Poornima IG, Parikh P, Shannon RP: D.